The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Luis M Ruilope, MD looked at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.

Video navigation menu

Diabetes confers an increased risk of CV morbidity and mortality, which is further aggravated by chronic kidney disease 0:09
Optimal management of diabetes with renal disease implies a broad strategy targeting various risk factors 1:50
Summary of how CKD complicates management of diabetic patients 6:25
Unmet needs in management of diabetic patients with CKD 9:04

Educational information

To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Disclosures

Luis M Ruilope, MD, Hospital 12 de Octubre Madrid, Spain

CME Accreditation

This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.

Funding

The symposium was supported by an unrestricted educational grant from Resverlogix Corp

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.